Uterine Cervical Neoplasms
Conditions
Keywords
HPV, Type 16, 18, E6E7, Immune therapeutic vaccine
Brief summary
BVAC-C is an immunotherapeutic vaccine using B-Cell and Monocytes as antigen-presenting cells. This study is consists of 2 parts. Phase I is for safety evaluation, and Phase IIa is for efficacy assessment.
Detailed description
BVAC-C is an immunotherapeutic vaccine using B-Cell and Monocytes as antigen-presenting cells. This study is consists of 2 parts(Phase I, Phase II). Phase I study is Open-label, dose-escalation, multiple dosing study to evaluate the safety, tolerability, immune response and preliminary efficacy of BVAC-C in patients with multiple metastatic progressive or recurrent HPV type 16 or 18 positive cervical cancer after failure to standard care. 9\ 18 patients will be enrolled In Phase IIa study, which Open-label, sequential assignment multiple dosing study, efficacy, immune response and safety will be evaluated. Total 21 patients will be enrolled in 3 groups.
Interventions
DRUGBVAC-C
Autologous B cells and monocytes transfected with E6E7 gene of HPV
DRUGTopotecan
Sponsors
Cellid Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with multiple metastatic progressive or recurrent HPV type 16 or 18 positive cervical cancer * Patients has received 1 or more platinum based doublet chemotherapy as prior therapy for progressive or recurrent tumor lesion (prior therapy does not include platinum chemotherapy given with radiation therapy for 1st line treatment before progression or recurrence) * Patients with at least 1 measurable lesion according to RECIST * Female patients between ages of 20 to 70 * Patients with ECOG performance status between 0 to 2 * Patients meets the blood test standards in the screening test * ANC≥1500/μL * LLN ≤ALC ≤ULN * Platelets≥100,000/μL * Hemoglobin\> 9g/dL * Patients meets the blood chemistry test standards in the screening test * Serum creatinine ≤ 2.0 mg/dL * Calculated creatinine clearance ≥ 50 mL/min * Serum bilirubin ≤1.5 x ULN * ALT and AST ≤2.5 × ULN (≤ 5 x ULN in patients with liver metastases) * Patients who has agreed to a medically accepted contraceptive in this clinical trial * Patients at least three months or more of survival can be expected * Patients decided to participate in this clinical trial and signed written informed consent
Exclusion criteria
* Patients histopathology is a neuroendocrine or small cell carcinoma * Patients with a history of brain metastasis or signs of brain metastasis * Patients tested positive in serological tests for hepatitis C virus or hepatitis B virus surface antigen, (HBsAg) or human immunodeficiency virus (HIV) * Patients with a history of HIV infection * Patients showing abnormal electrocardiogram , including arrhythmia * Patients have been administered the drug for other clinical trials within 4weeks before the screening visit * Patients have been administered any vaccines within 4weeks before the screening visit (eg. hepatitis A, hepatitis B, influenza, Td, etc. ) * Patients have been administered the blood products within 3 months before the screening visit * Patients have received chemotherapy or radiation therapy within 4weeks before the 1st administration of investigational drug (BVAC-C) * Patients treated with immunosuppressant or immunomodulatory agents within 6 months before the screening visit * Patients who have participated in the clinical trial of a therapeutic vaccine or immune therapy within 1 year before the screening visit * Patients with a history of serious allergic disease or serious side effects of the drug * Patients who is pregnant or breast-feeding * Patients researchers has determined that participation in the clinical trial is inappropriate * Patients suspected to have other primary cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate DLT with Clinical laboratory tests [Safety] | 12th week from first injection (End of trial) | Lymphocyte subset, Serum cytokine, NKT/NK cell assay, CD4/CD8 assay |
| Incidence of Serious Adverse Events assessed with CTCAE [Safety] | 12th week from first injection (End of trial) | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical laboratory tests | Screening visit and every 2 weeks from first injection (up to 12th week) | Blood chemistry, Serology |
| 12-lead ECG | Screening visit and Termination visit (12th week from first injection) | — |
| Vital signs | Every 2 weeks from first injection (up to 12th week) | Blood pressure, Pulse rate, Respiratory rate, Tympanic temperature |
| Physical examination | Screening, 6th week from first injection, 10th week from first injection and Termination visit (12th week from first injection) | Body weight |
Countries
South Korea
Outcome results
None listed